An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy
Abstract Purpose Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment which requires multiple vitreoretinal surgical interventions and frequent use of oil endotamponade. In this study, we conducted an in-depth analysis of complications associated with the use of heavy silico...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-024-03834-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585956180361216 |
|---|---|
| author | Maximilian Hammer Amanda Ie Katharina Eibenberger Gerd Uwe Auffarth Kanmin Xue |
| author_facet | Maximilian Hammer Amanda Ie Katharina Eibenberger Gerd Uwe Auffarth Kanmin Xue |
| author_sort | Maximilian Hammer |
| collection | DOAJ |
| description | Abstract Purpose Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment which requires multiple vitreoretinal surgical interventions and frequent use of oil endotamponade. In this study, we conducted an in-depth analysis of complications associated with the use of heavy silicone oil in the management of inferior PVR. Methods A retrospective cohort study of 20 eyes that underwent vitrectomy for inferior PVR with use of heavy silicone oil (Densiron 68) between March 2021 and October 2022 at Oxford Eye Hospital. Complications were classified into major categories relating to intraocular pressure, inflammation, lens, and oil emulsification/migration. Visual outcomes and surgical success rate were also evaluated. Results Fill-induced pressure spikes (> 30 mmHg) within 14 days post-surgery were common after Densiron tamponade, especially in patients previously on glaucoma drops. The number of glaucoma drugs were increased in 45% of patients during Densiron tamponade. In 20% of cases, an increased medication was continued long-term after Densiron removal. Significant cataract progression occurred in all phakic patients. In 25% of pseudophakic cases, posterior capsule opacification was noted. Inflammatory complications, such as anterior uveitis, were rare and any cystoid macular oedema was transient. No unexplained acute loss of vision following Densiron removal was encountered. The anatomical success rate at 30 days after Densiron removal was 70%. The mean (± SD) best-corrected visual acuities were 1.04 (± 0.79), 0.85 (± 0.62) and 0.50 (± 0.51) logMAR prior, during and after Densiron tamponade, respectively. Conclusion The outcomes in this cohort treated with Densiron 68 were comparable to previously reported anatomical and functional results in cases with inferior PVR. IOP and lens-related complications require additional treatment during or after Densiron tamponade. Inflammatory complications rarely occurred over tamponade durations of around three months. Trial registration Analyses were conducted as an internal quality improvement audit and as such did not require external IRB review. |
| format | Article |
| id | doaj-art-ee760632c4ae4990a205e4331350bdf6 |
| institution | Kabale University |
| issn | 1471-2415 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj-art-ee760632c4ae4990a205e4331350bdf62025-01-26T12:21:17ZengBMCBMC Ophthalmology1471-24152025-01-012511910.1186/s12886-024-03834-7An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathyMaximilian Hammer0Amanda Ie1Katharina Eibenberger2Gerd Uwe Auffarth3Kanmin Xue4Oxford Eye Hospital, Oxford University Hospitals NHS Foundation TrustOxford Eye Hospital, Oxford University Hospitals NHS Foundation TrustOxford Eye Hospital, Oxford University Hospitals NHS Foundation TrustDepartment of Ophthalmology and David J Apple Laboratory for Vision Research, Heidelberg University HospitalOxford Eye Hospital, Oxford University Hospitals NHS Foundation TrustAbstract Purpose Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment which requires multiple vitreoretinal surgical interventions and frequent use of oil endotamponade. In this study, we conducted an in-depth analysis of complications associated with the use of heavy silicone oil in the management of inferior PVR. Methods A retrospective cohort study of 20 eyes that underwent vitrectomy for inferior PVR with use of heavy silicone oil (Densiron 68) between March 2021 and October 2022 at Oxford Eye Hospital. Complications were classified into major categories relating to intraocular pressure, inflammation, lens, and oil emulsification/migration. Visual outcomes and surgical success rate were also evaluated. Results Fill-induced pressure spikes (> 30 mmHg) within 14 days post-surgery were common after Densiron tamponade, especially in patients previously on glaucoma drops. The number of glaucoma drugs were increased in 45% of patients during Densiron tamponade. In 20% of cases, an increased medication was continued long-term after Densiron removal. Significant cataract progression occurred in all phakic patients. In 25% of pseudophakic cases, posterior capsule opacification was noted. Inflammatory complications, such as anterior uveitis, were rare and any cystoid macular oedema was transient. No unexplained acute loss of vision following Densiron removal was encountered. The anatomical success rate at 30 days after Densiron removal was 70%. The mean (± SD) best-corrected visual acuities were 1.04 (± 0.79), 0.85 (± 0.62) and 0.50 (± 0.51) logMAR prior, during and after Densiron tamponade, respectively. Conclusion The outcomes in this cohort treated with Densiron 68 were comparable to previously reported anatomical and functional results in cases with inferior PVR. IOP and lens-related complications require additional treatment during or after Densiron tamponade. Inflammatory complications rarely occurred over tamponade durations of around three months. Trial registration Analyses were conducted as an internal quality improvement audit and as such did not require external IRB review.https://doi.org/10.1186/s12886-024-03834-7Vitreoretinal surgeryRetinal detachmentSilicone oilEndotamponadeProliferative vitreoretinopathyPVR |
| spellingShingle | Maximilian Hammer Amanda Ie Katharina Eibenberger Gerd Uwe Auffarth Kanmin Xue An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy BMC Ophthalmology Vitreoretinal surgery Retinal detachment Silicone oil Endotamponade Proliferative vitreoretinopathy PVR |
| title | An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy |
| title_full | An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy |
| title_fullStr | An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy |
| title_full_unstemmed | An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy |
| title_short | An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy |
| title_sort | analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy |
| topic | Vitreoretinal surgery Retinal detachment Silicone oil Endotamponade Proliferative vitreoretinopathy PVR |
| url | https://doi.org/10.1186/s12886-024-03834-7 |
| work_keys_str_mv | AT maximilianhammer ananalysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT amandaie ananalysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT katharinaeibenberger ananalysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT gerduweauffarth ananalysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT kanminxue ananalysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT maximilianhammer analysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT amandaie analysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT katharinaeibenberger analysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT gerduweauffarth analysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy AT kanminxue analysisofheavysiliconeoiltreatmentforinferiorproliferativevitreoretinopathy |